☆ 3.8 Meeting Abstract

The correlation between Topoisomerase-1 (Topo1) expression and outcome of treatment with capecitabine and irinotecan in advanced colorectal cancer (ACC) patients (pts) treated in the CAIRO study of the Dutch Colorectal Cancer Group (DCCG)

EJC SUPPLEMENTS (2009)

Journal

EJC SUPPLEMENTS

Volume 7, Issue 2, Pages 321-322

Publisher

PERGAMON-ELSEVIER SCIENCE LTD

DOI: 10.1016/S1359-6349(09)71098-5

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Effectiveness and safety of capecitabine, irinotecan and panitumumab in advanced colorectal cancer

Pui Lam Yip, Wai Him Brian Fung, Francis Ann Shing Lee, Chak Fei Lee, Natalie Sean Man Wong, Shing Fung Lee

Summary: This retrospective study reports the real-world effectiveness and safety of modified CAPIRI-P (mCAPIRI-P) regimen in patients with metastatic colorectal cancer. The results show that mCAPIRI-P is a safe and effective first-line treatment for RAS wild-type advanced colorectal cancer, and further research is warranted.

FRONTIERS IN ONCOLOGY (2023)

Add to Collection

Article Multidisciplinary Sciences

Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines

Yeong Hak Bang, Jeong Eun Kim, Ji Sung Lee, Sun Young Kim, Kyu-Pyo Kim, Tae Won Kim, Yong Sang Hong

Summary: The study evaluated the efficacy of bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer, finding that this combination showed significant disease control rates and survival outcomes in patients who had progressed with prior standard treatments.

SCIENTIFIC REPORTS (2021)

Add to Collection

Article Oncology

Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancer

Hiroyuki Arai, Yi Xiao, Joshua Millstein, Jingyuan Wang, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Wu Zhang, Christoph Mancao, Bodour Salhia, Shannon M. Mumenthaler, Aparna R. Parikh, Heinz-Josef Lenz

Summary: The study found TIMELESS rs2291739 may have different effects on the therapeutic efficacy of oxaliplatin- and irinotecan-based chemotherapy. This finding could be useful for personalized approaches in the first-line treatment of metastatic colorectal cancer.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection

Article Plant Sciences

Caffeine enhances chemosensitivity to irinotecan in the treatment of colorectal cancer

Seobin Yoon, Bum-Kyu Lee, Keun Pil Kim

Summary: The study found that caffeine can enhance the sensitivity of colorectal cancer cells to irinotecan, inhibit cell proliferation, induce cell death, and hinder DNA repair and cell cycle progression. This combination treatment resulted in more severe effects, including DNA fragmentation and mitotic catastrophe.

PHYTOMEDICINE (2023)

Add to Collection

Article Oncology

Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a retrospective cohort study

Xiu Liu, Kai Ou, Xiaoting Ma, Lizhen Gao, Qi Wang, Haizeng Zhang, Lin Yang

Summary: The use of the XELOXIRI regimen with or without targeted drugs was effective, with a manageable toxicity profile in Chinese patients with mCRC.

BMC CANCER (2022)

Add to Collection

Article Oncology

Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer

Thomas J. George, Alison M. Ivey, Azka Ali, Ji-Hyun Lee, Yu Wang, Karen C. Daily, Brian H. Ramnaraign, Sanda A. Tan, Krista P. Terracina, Thomas E. Read, Long H. Dang, Atif Iqbal

Summary: The study investigated the combination therapy of sorafenib and capecitabine in refractory metastatic colorectal cancer, showing a median progression-free survival of 6.2 months with manageable toxicity. This oral doublet therapy warrants further investigation for clinical use in patients with mCRC.

ONCOLOGIST (2021)

Add to Collection

Article Medicine, Research & Experimental

LEF1 silencing sensitizes colorectal cancer cells to oxaliplatin, 5-FU, and irinotecan

Elham Fakhr, Fatemeh Zare, Kayhan Azadmanesh, Ladan Teimoori-Toolabi

Summary: LEF1 plays an important role in the chemo-resistance of colorectal cancer cells, with downregulation of the long isoform making cells more sensitive to chemotherapy through reduced proliferation, increased apoptosis, or cell cycle arrest. Balancing the expression of long and short isoforms of LEF1 is crucial in overcoming chemo-resistance.

BIOMEDICINE & PHARMACOTHERAPY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Berberine Improves Irinotecan-Induced Intestinal Mucositis Without Impairing the Anti-colorectal Cancer Efficacy of Irinotecan by Inhibiting Bacterial β-glucuronidase

Bei Yue, Ruiyang Gao, Cheng Lv, Zhilun Yu, Hao Wang, Xiaolong Geng, Zhengtao Wang, Wei Dou

Summary: The study demonstrated that berberine could alleviate CPT11-induced gastrointestinal mucositis and protect intestinal barrier function, reducing toxic side-effects. Berberine acted by inhibiting bacterial GUS enzyme, thus maintaining the anti-tumor efficacy of CPT11.

FRONTIERS IN PHARMACOLOGY (2021)

Add to Collection

Article Pharmacology & Pharmacy

Translational Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Oxaliplatin and Irinotecan in Colorectal Cancer

Jinwei Zhu, Yicui Zhang, Yixin Zhao, Jingwei Zhang, Kun Hao, Hua He

Summary: Despite limited methods for translating organoid-based study results to clinical response, this study developed a PK/PD model using oxaliplatin and irinotecan treatments with colorectal cancer as examples. The model can predict PK profiles and responses following treatments, and may aid in decision-making in drug development and clinical trial design.

PHARMACEUTICS (2023)

Add to Collection

Article Multidisciplinary Sciences

Combining gut microbiota modulation and chemotherapy by capecitabine-loaded prebiotic nanoparticle improves colorectal cancer therapy

Tianqun Lang, Runqi Zhu, Xiao Zhu, Wenlu Yan, Yu Li, Yihui Zhai, Ting Wu, Xin Huang, Qi Yin, Yaping Li

Summary: Gut microbiota plays a significant role in colorectal cancer (CRC) therapy. Researchers have developed nanoparticles loaded with the chemotherapy drug capecitabine, which are made from prebiotic micelles. These nanoparticles enhance the probiotic response, increase anti-tumour immunity, and improve survival in CRC preclinical murine models when administered orally. This prebiotics-based nanoparticle shows promise as a combination therapy for CRC by modulating gut microbiota and providing chemotherapy.

NATURE COMMUNICATIONS (2023)

Add to Collection

Article Oncology

Advanced colorectal cancer subtypes (aCRCS) help select oxaliplatin-based or irinotecan-based therapy for colorectal cancer

Shin Takahashi, Yasuhiro Sakamoto, Tadamichi Denda, Atsuo Takashima, Yoshito Komatsu, Masato Nakamura, Hisatsugu Ohori, Tatsuro Yamaguchi, Yoshimitsu Kobayashi, Hideo Baba, Masanori Kotake, Kenji Amagai, Hitoshi Kondo, Ken Shimada, Atsushi Sato, Satoshi Yuki, Akira Okita, Kota Ouchi, Keigo Komine, Mika Watanabe, Satoshi Morita, Chikashi Ishioka

Summary: The study found that the advanced colorectal cancer subtype (aCRCS) may serve as a potential biomarker for predicting treatment responses to oxaliplatin and irinotecan in metastatic colorectal cancer patients, showing that some patients had better responses to IRI.

CANCER SCIENCE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Integrated Bioinformatics Analysis of the Hub Genes Involved in Irinotecan Resistance in Colorectal Cancer

Jakub Kryczka, Joanna Boncela

Summary: Different drug combinations, including irinotecan, are important in treating colorectal cancer (CRC). However, chemotherapy often leads to drug resistance. This study compared mRNA expression profiles of CRC cell lines and patient samples to select new candidate genes for irinotecan resistance. The results showed that in vitro models have limitations and cannot fully reflect the complex drug resistance network observed in patients.

BIOMEDICINES (2022)

Add to Collection

Article Oncology

Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer

Pietro Paolo Vitiello, Giulia Martini, Luigi Mele, Emilio Francesco Giunta, Vincenzo De Falco, Davide Ciardiello, Valentina Belli, Claudia Cardone, Nunzia Matrone, Luca Poliero, Virginia Tirino, Stefania Napolitano, Carminia Della Corte, Francesco Selvaggi, Gianpaolo Papaccio, Teresa Troiani, Floriana Morgillo, Vincenzo Desiderio, Fortunato Ciardiello, Erika Martinelli

Summary: This study demonstrates that a subset of CRCs with heterozygous ATM mutations may benefit from combination treatment with low doses of niraparib and irinotecan, suggesting a new potential approach in the treatment of ATM-mutated CRC, which should be prospectively validated in clinical trials.

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)

Add to Collection

Article Oncology

Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine

Afshin Derakhshani, Shahryar Hashemzadeh, Zahra Asadzadeh, Mahdi Abdoli Shadbad, Farnaz Rasibonab, Hossein Safarpour, Vahid Jafarlou, Antonio Giovanni Solimando, Vito Racanelli, Pankaj Kumar Singh, Souzan Najafi, Darya Javadrashid, Oronzo Brunetti, Nicola Silvestris, Behzad Baradaran

Summary: The study revealed an increasing trend of CTLA-4 in colorectal cancer (CRC) and the inhibitory molecule can be suppressed by the chemotherapy drug capecitabine. Inhibiting CTLA-4 can reactivate immune cells against tumors, potentially enhancing treatment outcomes.

CANCERS (2021)

Add to Collection

Article Oncology

Adjuvant Capecitabine and Oxaliplatin for Elderly Patients with Colorectal Cancer

Kazuaki Okamoto, Hiroaki Nozawa, Shigenobu Emoto, Koji Murono, Kazuhito Sasaki, Soichiro Ishihara

Summary: This study aimed to investigate the tolerability and efficacy of adjuvant CAPOX therapy in elderly patients compared to young patients. The results showed that adjuvant CAPOX therapy was well-tolerated in elderly Japanese patients, and the prognosis of elderly patients with stage III CRC was similar to that of their younger counterparts. Therefore, advanced age may not be a contraindication for adjuvant chemotherapy in CRC.

ONCOLOGY (2022)

Add to Collection

Article Medicine, Research & Experimental

Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer

Louise C. Brown, Janet Graham, David Fisher, Richard Adams, Jenny Seligmann, Matthew Seymour, Richard Kaplan, Emma Yates, Mahesh Parmar, Susan D. Richman, Philip Quirke, Rachel Butler, Kaikeen Shiu, Gary Middleton, Leslie Samuel, Richard H. Wilson, Timothy S. Maughan

Summary: FOCUS4 is a molecularly stratified umbrella trial in metastatic colorectal cancer, using adaptive statistical methodology to close sub-trials and add new therapies. Feedback from investigators at the close of the trial was consolidated into recommendations and lessons learned for similar future trials.

CLINICAL TRIALS (2022)

Add to Collection

Article Pathology

FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing

Susan D. Richman, Gemma Hemmings, Helen Roberts, Niall Gallop, Rachel Dodds, Lyndsay Wilkinson, Jonathan Davis, Rhian White, Emma Yates, Bharat Jasani, Louise Brown, Tim S. Maughan, Rachel Butler, Philip Quirke, Richard Adams

Summary: FOCUS4 trial is a successful umbrella trial for patients with advanced colorectal cancer, using molecular profiling for biomarker analysis.

JOURNAL OF CLINICAL PATHOLOGY (2023)

Add to Collection

Article Health Policy & Services

Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer

Raymond H. Henderson, Declan French, Ethna McFerran, Richard Adams, Harpreet Wasan, Robert Glynne-Jones, David Fisher, Susan Richman, Philip D. Dunne, Lisa Wilde, Timothy S. Maughan, Richard Sullivan, Mark Lawler

Summary: Health economic analyses compared the cost-effectiveness of intermittent and continuous cetuximab for colorectal cancer patients, showing cost savings and improved quality of life with intermittent treatment. These results helped support policy change, reduce unnecessary treatment, and underscored the importance of treatment breaks in reducing treatment toxicity.

JOURNAL OF CANCER POLICY (2022)

Add to Collection

Article Oncology

Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial

Dion Morton, Matthew Seymour, Laura Magill, Kelly Handley, James Glasbey, Bengt Glimelius, Andy Palmer, Jenny Seligmann, Soren Laurberg, Keigo Murakami, Nick West, Philip Quirke, Richard Gray, FOxTROT Collaborative Grp

Summary: Neoadjuvant chemotherapy shows potential benefits for locally advanced colon cancer compared to postoperative chemotherapy. In this study, patients with radiologically staged T3-4, N0-2, M0 colon cancer were randomly assigned to receive 6 weeks of preoperative oxaliplatin-fluoropyrimidine chemotherapy followed by either 18 or 24 weeks postoperatively. Results indicate that neoadjuvant chemotherapy results in marked downstaging of tumors and lower rates of incomplete resections and disease recurrence within 2 years.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Review Oncology

FOxTROT2: innovative trial design to evaluate the role of neoadjuvant chemotherapy for treating locally advanced colon cancer in older adults or those with frailty

J. R. Platt, O. M. Todd, P. Hall, Z. Craig, A. Quyn, M. Seymour, M. Braun, J. Roodhart, C. Punt, N. Christou, J. Taieb, M. Karoui, J. Brown, D. A. Cairns, D. Morton, A. Gilbert, J. F. Seligmann

Summary: Treating older adults with cancer is important, but there is a lack of high-quality evidence for their optimal management. Historic under-recruitment of older adults in clinical trials limits our understanding of how existing evidence can be applied to this group. Challenges in conducting clinical trials in older adults impact the clinical relevance of results and limit their representativeness.

ESMO OPEN (2023)

Add to Collection

Article Oncology

Female Sex but Not Oestrogen Receptor Expression Predicts Survival in Advanced Gastroesophageal Adenocarcinoma-A Post-hoc Analysis of the GO2 Trial

Mark A. Baxter, Lindsay C. Spender, Shaun Walsh, Susan Bray, Gemma Skinner, Sharon S. King, Peter S. Hall, Matthew J. Seymour, Russell D. Petty

Summary: Gastroesophageal adenocarcinoma (GOA) is a cancer with poor survival, but females have better outcomes. The reason for this is unknown. A study using samples from a clinical trial found no clear link between outcome and oestrogen receptor expression, but observed improved survival with older age and female sex.

CANCERS (2023)

Add to Collection

Article Cell Biology

Generalizable biomarker prediction from cancer pathology slides with self-supervised deep learning: A retrospective multi-centric study

Jan Moritz Niehues, Philip Quirke, Nicholas P. West, Heike I. Grabsch, Marko van Treeck, Yoni Schirris, Gregory P. Veldhuizen, Gordon G. A. Hutchins, Susan D. Richman, Sebastian Foersch, Titus J. Brinker, Junya Fukuoka, Andrey Bychkov, Wataru Uegami, Daniel Truhn, Hermann Brenner, Alexander Brobeil, Michael Hoffmeister, Jakob Nikolas Kather

Summary: Deep learning can predict microsatellite instability (MSI) from routine histopathology slides of colorectal cancer (CRC). It is unclear whether DL can also predict other biomarkers with high performance and whether DL predictions generalize to external patient populations.

CELL REPORTS MEDICINE (2023)

Add to Collection

Article Oncology

Transformer-based biomarker prediction from colorectal cancer histology: A large-scale multicentric study

Sophia J. Wagner, Daniel Reisenbuechler, Nicholas P. West, Jan Moritz Niehues, Jiefu Zhu, Sebastian Foersch, Gregory Patrick Veldhuizen, Philip Quirke, Heike I. Grabsch, Piet A. van den Brandt, Gordon G. A. Hutchins, Susan D. Richman, Tanwei Yuan, Rupert Langer, Josien C. A. Jenniskens, Kelly Offermans, Wolfram Mueller, Richard Gray, Stephen B. Gruber, Joel K. Greenson, Gad Rennert, Joseph D. Bonner, Daniel Schmolze, Jitendra Jonnagaddala, Nicholas J. Hawkins, Robyn L. Ward, Dion Morton, Matthew Seymour, Laura Magill, Marta Nowak, Jennifer Hay, Viktor H. Koelzer, David N. Church, Christian Matek, Carol Geppert, Chaolong Peng, Cheng Zhi, Xiaoming Ouyang, Jacqueline A. James, Maurice B. Loughrey, Manuel Salto-Tellez, Hermann Brenner, Michael Hoffmeister, Daniel Truhn, Julia A. Schnabel, Melanie Boxberg, Tingying Peng, Jakob Nikolas Kather

Summary: This study develops a new transformer-based pipeline for predicting prognostic biomarkers from colorectal cancer pathology slides. The results show that this approach significantly improves performance, generalizability, data efficiency, and interpretability compared to current algorithms. The method also solves a longstanding diagnostic problem by achieving clinical-grade performance on endoscopic biopsy tissue.

CANCER CELL (2023)

Add to Collection

Letter Oncology

Reply to S. Chakrabarti et al, R. Cohen et al, and DC Guven

Richard Gray, Matt Seymour, Laura Magill, Kelly Handley, Philip Quirke, Nick West, Dion Morton

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Meeting Abstract Oncology

The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC).

Jenny F. Seligmann, Enric Domingo, David Fisher, Faye Elliott, Louise C. Brown, Matthew T. Seymour, Susan Richman, Philip Quirke, Rachel Butler, Helen Roberts, Carme Camps, Pamela Kaisaki, David N. Church, David James Kerr, Rachel Kerr, Richard H. Wilson, Oliver Sieber, Jenny Taylor, Ian Tomlinson, Tim Maughan

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Meeting Abstract Oncology

A biomarker enrichment trial of anti-EGFR agents in right primary tumor location (rPTL), RAS wild-type (RAS-wt) advanced colorectal cancer (aCRC): ARIEL (ISRCTN11061442)

Christopher Williams, Jake Emmerson, Andrew David Beggs, Nicholas West, John A. Bridgewater, Janet Graham, Matthew T. Seymour, Gemma Hemmings, Claire Dimbleby, Geraldine A. Murden, Alexandra Gilbert, David M. Meads, David A. Cairns, Richard Adams, Jenny F. Seligmann

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First-and Second-Line Clinical Trials

Nadine J. McCleary, William S. Harmsen, Ellana Haakenstad, James M. Cleary, Jeffrey A. Meyerhardt, John Zalcberg, Richard Adams, Axel Grothey, Alberto F. Sobrero, Eric Van Cutsem, Richard M. Goldberg, Marc Peeters, Josep Tabernero, Matt Seymour, Leonard B. Saltz, Bruce J. Giantonio, Dirk Arnold, Mace L. Rothenberg, Miriam Koopman, Hans-Joachim Schmoll, Henry C. Pitot, Paulo M. Hoff, Niall Tebbutt, Gianluca Masi, John Souglakos, Carsten Bokemeyer, Volker Heinemann, Takayuki Yoshino, Benoist Chibaudel, Aimery deGramont, Qian Shi, Stuart M. Lichtman

Summary: This study evaluated the time to progression and survival outcomes of second-line therapy for metastatic colorectal cancer in older adults aged 70 years and older compared with younger adults. It found that older adults were less likely to receive second-line therapy, but there was no statistically significant difference in survival outcomes between older and younger adults following second-line therapy.

JNCI CANCER SPECTRUM (2022)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.